Literature DB >> 12970777

Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.

J G Shelton1, P W Moye, L S Steelman, W L Blalock, J T Lee, R A Franklin, M McMahon, J A McCubrey.   

Abstract

The Raf/MEK/ERK and PI3K/Akt pathways regulate proliferation and prevent apoptosis, and their altered expression is commonly observed in human cancer due to the high mutation frequency of upstream regulators. In this study, the effects of Raf, MEK, and PI3K inhibitors on conditionally transformed hematopoietic cells were examined to determine if they would display cytotoxic differences between cytokine- and oncogene-mediated proliferation, and whether inhibition of both pathways was a more effective means to induce apoptosis. In the hematopoietic model system employed, proliferation was conditional and occurred when either interleukin-3 (IL-3) or the estrogen receptor antagonist 4-hydroxytamoxifen (4HT), which activates the conditional oncoprotein (DeltaRaf:ER), were provided. Thus, upon the addition of the signal transduction inhibitors and either IL-3 or 4HT, the effects of these drugs were examined in the same cell under 'cytokine-' and 'oncoprotein' -mediated growth conditions avoiding genetic and differentiation stage heterogeneity. At drug concentrations around the reported IC(50) for the Raf inhibitor L-779,450, it suppressed DNA synthesis and induced apoptosis in hematopoietic FDC-P1 cells transformed to grow in response to either Raf-1 or A-Raf (FD/DeltaRaf-1:ER and FD/DeltaA-Raf:ER), but it displayed less effects on DNA synthesis and apoptosis when the cells were cultured in IL-3. This Raf inhibitor was less effective on B-Raf- or MEK1-responsive cells, demonstrating the specificity of this drug. MEK inhibitors also suppressed DNA synthesis and induced apoptosis in Raf-responsive cells and the effects were more significant on Raf-responsive compared to cytokine-mediated growth. The PI3K inhibitor LY294002 suppressed Raf-mediated growth, indicating that part of the long-term proliferative effects mediated by Raf are PI3K dependent. Simultaneous inhibition of both Raf/MEK/ERK and PI3K/Akt pathways proved a more efficient means to suppress DNA synthesis and induce apoptosis at lower drug concentrations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970777     DOI: 10.1038/sj.leu.2403052

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  14 in total

1.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

2.  RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.

Authors:  Anja Berger; Sandra-Annika Quast; Michael Plötz; Nicholas-Frederik Kuhn; Uwe Trefzer; Jürgen Eberle
Journal:  J Invest Dermatol       Date:  2013-08-16       Impact factor: 8.551

3.  The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.

Authors:  Bao Hoang; Angelica Benavides; Yijiang Shi; Yonghui Yang; Patrick Frost; Joseph Gera; Alan Lichtenstein
Journal:  J Biol Chem       Date:  2012-05-03       Impact factor: 5.157

Review 4.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

Review 5.  New perspectives for targeting RAF kinase in human cancer.

Authors:  Zoi Karoulia; Evripidis Gavathiotis; Poulikos I Poulikakos
Journal:  Nat Rev Cancer       Date:  2017-10-06       Impact factor: 60.716

6.  MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation.

Authors:  W Zhao; H He; K Ren; B Li; H Zhang; Y Lin; R-G Shao
Journal:  Blood Cancer J       Date:  2013-03-29       Impact factor: 11.037

7.  Evaluating Inhibition of the Epidermal Growth Factor (EGF)-Induced Response of Mutant MCF10A Cells with an Acoustic Sensor.

Authors:  Marcela P Garcia; Ammar Shahid; Jennifer Y Chen; Jun Xi
Journal:  Biosensors (Basel)       Date:  2012-11-13

8.  The function and dynamics of the apical scaffolding protein E3KARP are regulated by cell-cycle phosphorylation.

Authors:  Cécile Sauvanet; Damien Garbett; Anthony Bretscher
Journal:  Mol Biol Cell       Date:  2015-08-26       Impact factor: 4.138

9.  Multiple model-informed open-loop control of uncertain intracellular signaling dynamics.

Authors:  Jeffrey P Perley; Judith Mikolajczak; Marietta L Harrison; Gregery T Buzzard; Ann E Rundell
Journal:  PLoS Comput Biol       Date:  2014-04-10       Impact factor: 4.475

10.  Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways.

Authors:  Yu Wang; Hao Nie; Xin Zhao; Yong Qin; Xingguo Gong
Journal:  BMC Cancer       Date:  2016-09-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.